Literature DB >> 25642631

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.

Adam Shlien1, Brittany B Campbell2, Richard de Borja3, Ludmil B Alexandrov4, Daniele Merico5, David Wedge4, Peter Van Loo6, Patrick S Tarpey4, Paul Coupland7, Sam Behjati4, Aaron Pollett8, Tatiana Lipman9, Abolfazl Heidari9, Shriya Deshmukh9, Na'ama Avitzur9, Bettina Meier10, Moritz Gerstung4, Ye Hong10, Diana M Merino3, Manasa Ramakrishna4, Marc Remke11, Roland Arnold3, Gagan B Panigrahi3, Neha P Thakkar12, Karl P Hodel13, Erin E Henninger13, A Yasemin Göksenin13, Doua Bakry14, George S Charames15, Harriet Druker16, Jordan Lerner-Ellis17, Matthew Mistry2, Rina Dvir18, Ronald Grant14, Ronit Elhasid18, Roula Farah19, Glenn P Taylor20, Paul C Nathan14, Sarah Alexander14, Shay Ben-Shachar21, Simon C Ling22, Steven Gallinger23, Shlomi Constantini24, Peter Dirks25, Annie Huang26, Stephen W Scherer27, Richard G Grundy28, Carol Durno29, Melyssa Aronson30, Anton Gartner10, M Stephen Meyn31, Michael D Taylor25, Zachary F Pursell13, Christopher E Pearson12, David Malkin32, P Andrew Futreal4, Michael R Stratton4, Eric Bouffet26, Cynthia Hawkins33, Peter J Campbell34, Uri Tabori35.   

Abstract

DNA replication-associated mutations are repaired by two components: polymerase proofreading and mismatch repair. The mutation consequences of disruption to both repair components in humans are not well studied. We sequenced cancer genomes from children with inherited biallelic mismatch repair deficiency (bMMRD). High-grade bMMRD brain tumors exhibited massive numbers of substitution mutations (>250/Mb), which was greater than all childhood and most cancers (>7,000 analyzed). All ultra-hypermutated bMMRD cancers acquired early somatic driver mutations in DNA polymerase ɛ or δ. The ensuing mutation signatures and numbers are unique and diagnostic of childhood germ-line bMMRD (P < 10(-13)). Sequential tumor biopsy analysis revealed that bMMRD/polymerase-mutant cancers rapidly amass an excess of simultaneous mutations (∼600 mutations/cell division), reaching but not exceeding ∼20,000 exonic mutations in <6 months. This implies a threshold compatible with cancer-cell survival. We suggest a new mechanism of cancer progression in which mutations develop in a rapid burst after ablation of replication repair.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25642631     DOI: 10.1038/ng.3202

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  126 in total

Review 1.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

3.  Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  A Kerpel; M Yalon; M Soudack; J Chiang; A Gajjar; K E Nichols; Z Patay; S Shrot; C Hoffmann
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

4.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

Review 5.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

6.  POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome.

Authors:  Davor Lessel; Fuki M Hisama; Katalin Szakszon; Bidisha Saha; Alexander Barrios Sanjuanelo; Bonnie A Salbert; Pamela D Steele; Jennifer Baldwin; W Ted Brown; Charles Piussan; Henri Plauchu; Judit Szilvássy; Edit Horkay; Josef Högel; George M Martin; Alan J Herr; Junko Oshima; Christian Kubisch
Journal:  Hum Mutat       Date:  2015-08-06       Impact factor: 4.878

7.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

8.  Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade.

Authors:  Melissa A Galati; Karl P Hodel; Zachary F Pursell; Uri Tabori; Miki S Gams; Sumedha Sudhaman; Taylor Bridge; Walter J Zahurancik; Nathan A Ungerleider; Vivian S Park; Ayse B Ercan; Lazar Joksimovic; Iram Siddiqui; Robert Siddaway; Melissa Edwards; Richard de Borja; Dana Elshaer; Jiil Chung; Victoria J Forster; Nuno M Nunes; Melyssa Aronson; Xia Wang; Jagadeesh Ramdas; Andrea Seeley; Tomasz Sarosiek; Gavin P Dunn; Jonathan N Byrd; Oz Mordechai; Carol Durno; Alberto Martin; Adam Shlien; Eric Bouffet; Zucai Suo; James G Jackson; Cynthia E Hawkins; Cynthia J Guidos
Journal:  Cancer Res       Date:  2020-09-16       Impact factor: 12.701

Review 9.  Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Authors:  Erika K S M Leenders; Harm Westdorp; Roger J Brüggemann; Jan Loeffen; Christian Kratz; John Burn; Nicoline Hoogerbrugge; Marjolijn C J Jongmans
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

10.  Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences.

Authors:  Lawrence A Loeb
Journal:  Cancer Res       Date:  2016-04-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.